INFU
InfuSystem Holdings, Inc.
INFU offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
LLY
Eli Lilly and Company
LLY has the edge over INFU overall, supported by stronger fundamentals and lower modeled downside.
INFU Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
INFU's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
INFU PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 25x | $14.79 | — |
| Cheap | 28x | $12.19 | -18% |
| Current | 34x | $14.79 | — |
| Fair | 50x | $21.97 | +49% |
| Expensive | 333x | $146 | +890% |
Historical ranges are pointers, not guarantees.
INFU has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
INFU Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect INFU's earnings to grow and its profitability to improve, with its revenue holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over INFU on the outlook, with more favorable revenue expectations.
INFU Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.59 | +34% |
| Q3 2026 | $0.44 | +63% |
| Q2 2026 | $0.40 | +67% |
| Q1 2026 | $0.37 | +147% |
| Q4 2025 | $0.31 | +182% |
| Q3 2025 | $0.27 | +286% |
| Q2 2025 | $0.24 | +1100% |
| Q1 2025 | $0.15 | +1400% |
| Q4 2024 | $0.11 | +175% |
INFU has the edge over LLY on earnings, with stronger typical year-over-year growth.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
INFU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $37.6M | +3% |
| Q2 2026 | $36.9M | +2.6% |
| Q1 2026 | $33.7M | -3% |
| Q4 2025 | $36.2M | +7% |
| Q3 2025 | $36.5M | +3.3% |
| Q2 2025 | $36M | +6.8% |
| Q1 2025 | $34.7M | +8.5% |
| Q4 2024 | $33.8M | +6.5% |
INFU's revenue grew through 2024 and has held roughly level since: $38M last quarter, up 3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | +2.2 points |
| Q2 2026 | 11% | +0.8 points |
| Q1 2026 | 4.7% | +2.9 points |
| Q4 2025 | 10% | +2.5 points |
| Q3 2025 | 10% | +1.2 points |
| Q2 2025 | 10% | +5 points |
| Q1 2025 | 1.8% | +4.4 points |
| Q4 2024 | 7.7% | +3.8 points |
INFU's operating margin was 13% last quarter, up 2.2 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over INFU on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over INFU on profitability, with a higher operating margin.
INFU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $10.3M | +22% |
| Q2 2026 | $6.7M | -1.6% |
| Q1 2026 | $813K | -51% |
| Q4 2025 | $7M | -5.5% |
| Q3 2025 | $8.4M | -14% |
| Q2 2025 | $6.8M | +244% |
| Q1 2025 | $1.6M | +746% |
| Q4 2024 | $7.4M | +74% |
INFU generated $25M in free cash flow over the past year, up 2.1% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over INFU on cash flow, with more consistent year-over-year improvement.
INFU Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +152K shares |
| 1 year | +0.6% | +126K shares |
| 3 years | -3% | -647K shares |
| 5 years | +2.4% | +494K shares |
| Available history | +1.1% | +233K shares |
INFU has 21M diluted shares, up 0.6% from a year ago, despite $6M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $605,000 |
| Q2 2026 | $3.5M |
| Q1 2026 | $809,000 |
| Q4 2025 | $1.3M |
| Q3 2025 | $2.2M |
| Q2 2025 | $3.5M |
| Q1 2025 | $2.9M |
| Q4 2024 | $199,000 |
INFU spent $6M buying back its own shares over the past year, down 28% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over INFU on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
INFU Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.4x | Very low |
| Q2 2026 | 0.7x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.7x | Very low |
| Q3 2025 | 0.8x | Very low |
| Q2 2025 | 1.1x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.2x | Healthy |
INFU has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
INFU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 73.2 | Overbought |
| Stochastic | 84.8 | Overbought |
INFU's weekly RSI is 73 (overbought) and its Stochastic is 85 (overbought).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
INFU PE vs Healthcare Sector
| Metric | INFU | Sector median | Relative |
|---|---|---|---|
| PE | 34x | 26x | 30% above |
| PE % | 31 | 29 | 2 pts above |
INFU has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
INFU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.7 | 8.3% above |
| 20 week MA | $12.1 | 22% above |
| 50 week MA | $10.3 | 44% above |
| 100 week MA | $8.93 | 66% above |
| 200 week MA | $8.82 | 68% above |
INFU is in an uptrend: it's above all five of its weekly moving averages, and 68% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
INFU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.22 | $19.0 | +131% |
| 2021 | $19.0 | $16.9 | -11% |
| 2022 | $16.9 | $8.50 | -50% |
| 2023 | $8.50 | $10.5 | +24% |
| 2024 | $10.5 | $8.14 | -23% |
| 2025 | $8.14 | $8.96 | +10% |
| 2026 YTD | $8.96 | $14.8 | +65% |
INFU has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.